Feds launching study on rare allergic reactions to Pfizer coronavirus vaccine
CVS Health pharmacists draw up a dose of the Pfizer COVID-19 vaccine at the Sivercrest Health and Rehabilitation Center in Crestview, Fla., Monday, Dec. 21, 2020. This was one of the first administrations of the vaccine in the state. (Michael Snyder/Northwest Florida Daily News via AP)
Published December 22. 2020 12:05AM
Joel Achenbach, The Washington Post
WASHINGTON - Officials at the National Institutes of Health are rushing to devise a study to find out why, in a few rare cases, people have had severe allergic reactions to the Pfizer coronavirus vaccine.
The goal is to identify the component of the vaccine most likely to be responsible for these potentially life-threatening incidents, known as anaphylaxis. No cases have yet been associated with the other newly authorized vaccine, made by Moderna, but it is being administered to the general public for the first time this week and has similar compon
US health authorities launch study of rare allergic reactions to coronavirus vaccine Updated: December 21, 2020 Published December 21, 2020
Share on Facebook
Print article WASHINGTON - Officials at the National Institutes of Health are rushing to devise a study to find out why, in a few rare cases, people have had severe allergic reactions to the Pfizer coronavirus vaccine. The goal is to identify the component of the vaccine most likely to be responsible for these potentially life-threatening incidents, known as anaphylaxis. No cases have yet been associated with the other newly authorized vaccine, made by Moderna, but it is being administered to the general public for the first time this week and has similar components to the one developed by Pfizer and its partner BioNTech.
The study will recruit volunteers who have had a history of severe allergic reactions and who will receive the vaccine under close clinical supervision, according to Daniel Rotrosen, director of the Division of Allergy, Immunology and Transplantation at the National Institute of Allergy and Infectious Diseases. This is not a simple study design, Rotrosen told
The Washington Post. We expect to be looking at highly allergic individuals. They will be not necessarily so easy to recruit, either. A lot still needs to be done to be sure we have the optimal study design. That said, we re trying to move as quickly as we can, for obvious reasons.
NIH devising study on rare allergic reactions to coronavirus vaccine Joel Achenbach
Replay Video UP NEXT Officials at the National Institutes of Health are rushing to devise a study to find out why, in a few rare cases, people have had severe allergic reactions to the Pfizer coronavirus vaccine. The goal is to identify the component of the vaccine most likely to be responsible for these potentially life-threatening incidents, known as anaphylaxis. No cases have yet been associated with the other newly authorized vaccine, made by Moderna, but it is being administered to the general public for the first time this week and has similar components to the one developed by Pfizer and its partner BioNTech.
Listen
Update RequiredTo play audio, update browser or Flash plugin.
In this Aug. 19, 2020 file photo, teachers Andrea Gordon, left, and Melissa Stacy go over plans for the possibility of classroom learning, among socially-distanced desks at Palm Vista Elementary School in Twentynine Palms, Calif.
AP Photo/Gregory Bull, File
California’s new regional stay-at-home order allows for schools that had already opened their campuses to keep them open but how safe is in-person learning?
CapRadio PolitiFact California reporter Chris Nichols joins CapRadio’s Mike Hagerty to discuss school safety during the pandemic.
This interview has been edited for clarity and length.